Boehringer submits Pradaxa antidote app; Sanofi's Lantus follow-up nears EMA approval;

> Boehringer Ingelheim has submitted an FDA application for its Pradaxa antidote. Release | More

> The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi's ($SNY) Lantus follow-up, Toujeo, for European approval. Report

> India's Natco Pharma is challenging the patent on Gilead's Sovaldi despite its licensing agreement to make and sell cheap versions of the drug. More (sub. req.)

> AstraZeneca ($AZN) has completed its deal for Actavis' ($ACT) North American respiratory portfolio. Brief

And Finally... Millennials aren't big on big purchases--even cars and houses--but they do like to spend money on health and fitness gadgets. Infographic